Masahiko Aoki

Dr. Masahiko Aoki

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in ESMO Open
Verified
Journal Article
Open access
PDF file
MAMasahiko Aoki
Masahiko Aoki
HSHirokazu Shoji
Hirokazu Shoji
KNKengo Nagashima
Kengo Nagashima
HIHiroshi Imazeki
Hiroshi Imazeki
TMTakahiro Miyamoto
Takahiro Miyamoto
NBNarikazu Boku
Narikazu Boku
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotecan. Methods The subjects of this retrospective study were patients with AGC with measurable lesions, and their tumour growth rates (TGR) during nivolumab or irinotecan were compared with those during prior therapy. HPD was defined as an increase in TGR more than twofold. Results 34 and 66 patients received nivolumab and irinotecan in third or later line between June 2009 and September 2018 at our hospital; 22 patients receiving nivolumab had prior treatment with irinotecan, and one patient received irinotecan after nivolumab. Nivolumab and irinotecan showed no differences in disease control rates (38.2% and 34.8%) and in progression-free survival (PFS) (HR 1.1, 95% CI 0.7 to 1.6, p=0.802). The incidence of HPD was slightly higher after nivolumab (29.4%) than after irinotecan (13.5%) (p=0.0656), showing no differences in background between the patients with and without HPD. Compared between HPD and PD other than HPD after nivolumab, the HRs for PFS and overall survival (OS) were 1.1 (95% CI 0.5 to 2.7; p=0.756), and 2.1 (95% CI 0.7 to 5.8; p=0.168), but such clear difference in OS was not observed after irinotecan. Conclusions HPD was observed more frequently after nivolumab compared with irinotecan, which was associated with a poor prognosis after nivolumab but not so clearly after irinotecan.

1 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MAMasahiko Aoki
Masahiko Aoki
HSHirokazu Shoji
Hirokazu Shoji
AKAyumi Kashiro
Ayumi Kashiro
KTKeiko Takeuchi
Keiko Takeuchi
YSYoshihiro Shimizu
Yoshihiro Shimizu
KHKazufumi Honda
Kazufumi Honda
The comprehensive analysis of biological and clinical aspects of circulating tumor cells (CTCs) has attracted interest as a means of enabling non-invasive, real-time monitoring of cancer patients and enhancing our fundamental understanding of tumor metastasis. However, CTC populations are extremely small when compared to other cell populations in the blood, limiting our comprehension of CTC biology and their clinical utility. Recently developed proteomic and genomic techniques that require only a small amount of sample have attracted much interest and expanded the potential utility of CTCs. Cancer heterogeneity, including specific mutations, greatly impacts disease diagnosis and the choice of available therapeutic strategies. The CTC population consists primarily of cancer stem cells, and CTC subpopulations are thought to undergo epithelial–mesenchymal transition during dissemination. To better characterize tumor cell populations, we demonstrated that changes in genomic profiles identified via next-generation sequencing of liquid biopsy samples could be expanded upon to increase sensitivity without decreasing specificity by using a combination of assays with CTCs and circulating tumor DNA. To enhance our understanding of CTC biology, we developed a metabolome analysis method applicable to single CTCs. Here, we review―omics studies related to CTC analysis and discuss various clinical and biological issues related to CTCs.

12 March 2018 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MAMasahiko Aoki
Masahiko Aoki
STSatoshi Tokioka
Satoshi Tokioka
KNKen Narabayashi
Ken Narabayashi
AHAkitoshi Hakoda
Akitoshi Hakoda
YIYosuke Inoue
Yosuke Inoue
KHKazuhide Higuchi
Kazuhide Higuchi
Laparoscopic and endoscopic cooperative surgery (LECS) was performed for the local resection of gastrointestinal stromal tumors (GIST). LECS enables less resection of the lesion area and preserves function. Furthermore, LECS can be safely performed and independent of tumor location. However, LECS is not usually used for cases involving gastric carcinoma because it may seed tumor cells into the peritoneal cavity when the gastric wall is perforated. Here, we report seven cases of LECS for intra-mucosal gastric carcinoma, which were difficult to carry out by endoscopic submucosal dissection (ESD) because of ulcer scars. We performed LECS (classical LECS and inverted LECS) in seven cases of intra-mucosal gastric carcinoma. All cases had ulcer scars beside the tumor. LECS was chosen because ESD was thought to be difficult because of the ulcer scars. We only selected cases in which the patients did not prefer gastrectomy and endoscopic examination was indicative of intra-mucosal gastric carcinoma. In all cases, LECS was performed without severe complications including postoperative stenosis. Histopathology findings proved that the tumors were intra-mucosal carcinoma and had been resected completely. Furthermore, there were ulcer scars (Ul IIIs-IVs) beside the tumor. Currently, dissemination and recurrence have not been apparent. LECS for intra-mucosal gastric carcinoma is an efficient procedure, but strict observation is necessary because of the possibility of peritoneal dissemination. Results suggest that LECS is likely to be effective for cases involving intra-mucosal gastric carcinoma that are difficult to treat by ESD due to ulcer scars.

1 February 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TTTetsuji Terazawa
Tetsuji Terazawa
HKHiroyuki Kodama
Hiroyuki Kodama
HYHiroki Yukami
Hiroki Yukami
MAMasahiko Aoki
Masahiko Aoki
TMTakahiro Miyamoto
Takahiro Miyamoto
KHKazuhide Higuchi
Kazuhide Higuchi
51 Background: The standard therapy for the locally advanced rectal cancer (LARC) (Ra or Rb, T2Npsitive, T3/4Nany) is chemoradiotherapy (CRT) followed by surgery. The CRT prevents local recurrence, although problems such as complications or the improvement of distant recurrence still remain. Several studies about the neoadjuvant chemotherapy (NAC) without radiation showed favorable R0 resection rate and outcome, however the best regimen of NAC is unclear. The aim of this study is to investigate the efficacy and safety of mFOLFOXIRI and CAPOX/SOX as NAC. Methods: We examined the patients (pts) with LARC who were planned to receive mFOLFOXIRI (5FU 2400mg/m2/day1-2, leucovorin 200mg/m2, oxaliplatin 85mg/m2, irinotecan 150mg/m2, every 2 weeks) or CAPOX/SOX(capecitabine 2000mg/m2 or S-1 mg/m2 80day1-14, oxaliplatin 130mg/m2, day1, every 3weeks) for 8-12 weeks as NAC, retrospectively. Results: Forty-nine pts received mFOLFOXIRI and thirty-two pts received XELOX/SOX between Jan 2015 and Mar 2019. The characteristics of mFOLFOXIRI and XELOX/SOX were as follows; median age, 64 (37-80) and 65 (33-68); PS 0/1, 46(94%)/3(6%) and 14(44%)/18(56%); Ra/Rb-P, 4(8%)/45(92%) and 0/32; clinical T2/3/4, 4(7%)/27(55%)/19(39%) and 1(3%)/18(56%)/13(41%); clinical N0/1/2, 13(27%)/26(53%)/10(20%) and 7(22%)/17(53%)/8(25%). The pathological response rate which was defined as tumor affected area over one-third were 61.2% in mFOLFOXIRI and 65.6% in CAPOX/SOX including complete remission of 4.1% and 12.5%, respectively. Six of 49 pts withdrew from mFOLFOXIRI due to toxicities, whereas one of 32 pts from CAPOX/SOX. One pt received CRT after SOX because of lack of efficacy. The major grade 3/4 toxicities of mFOLFOXIRI were neutropenia (n = 22, 45%), thrombocytopenia and febrile neutropenia (n = 4, 8%) and anorexia (n = 3, 6%), whereas CAPOX/SOX neutropenia (n = 3. 9%), thrombocytopenia (n = 1, 3%) and hand-foot syndrome (n = 1, 3%). The one year of relapse free survival rate were 85.4% and 83.6%. Conclusions: Although the pathological response of mFOLFOXIRI was comparable with CAPOX/SOX, CAPOX/SOX was less toxic.The further investigation including 5 year overall survival rate rate was needed.

1 January 2003 in Progress of Digestive Endoscopy
Verified
Journal Article
Open access
PDF file
FTFumiki Toriumi
Fumiki Toriumi
YSYoshiro Saikawa
Yoshiro Saikawa
KKKoichiro Kumai
Koichiro Kumai
MAMasahiko Aoki
Masahiko Aoki
NYNobunari Yoshimizu
Nobunari Yoshimizu
MKMasaki Kitajima
Masaki Kitajima
We report a 65-years-old woman of small mucosal gastric cancer with lymph nodes metastasis in N2 region, which is classified by the definitions of the Japanese Research Society for Gastric Cancer. Gastroscopy was performed when the patient complaint of epigastric pain, diagnosing small IIc-typed gastric cancer at the anterior wall of middle stomach. The size of cancer is 8 mm in diameter and cancer invasion was determined as mucosal cancer, preoperatively. As pathological examination revealed signet ring cell carcinoma in the lesion, we performed distal gastrectomy with lymph node dissection (D2) under laparotomy. Pathological diagnosis of the resected specimen showed signet ring cell carcinoma, 9 mm in diameter, pT1 (M) , INFβ, ly0, v0, pN2 lymph node metastasis (14/37[#3 (6/10) , #5 (1/3) , #7 (3/4) , #9 (4/7) ]) . The frequency of lymph node metastasis of mucosal gastric cancer was reported to be around 2%, and mucosal gastric cancer with N2 metastasis was very rare and was observed in the case with large tumor size. In this case report, we demonstrated a case with small mucosal gastric cancer with N2 lymph node metastasis, suggesting that critical determination of surgical method must be necessary in cases of signet ring cell carcinoma or undifferentiated adenocarcinoma, even in small mucosal gastric cancer.